Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 401Colorectal Neoplasms 317Rectal Neoplasms 235Stomach Neoplasms 209Pancreatic Neoplasms 137Neoplasm Metastasis 123Colonic Neoplasms 94Neoplasms 86Triple Negative Breast Neoplasms 64Esophageal Neoplasms 57Biliary Tract Neoplasms 39Nasopharyngeal Carcinoma 37Cholangiocarcinoma 31Adenocarcinoma 31Carcinoma, Hepatocellular 30Gallbladder Neoplasms 29Carcinoma, Non-Small-Cell Lung 21Bile Duct Neoplasms 21Locally Advanced Rectal Cancer 20Adenocarcinoma Of Esophagus 20Squamous Cell Carcinoma of Head and Neck 19Brain Neoplasms 19Gastrointestinal Neoplasms 18Parkinson Disease 4, Autosomal Dominant Lewy Body 17Liver Neoplasms 17Head and Neck Neoplasms 17Esophageal Squamous Cell Carcinoma 17Colorectal Cancer Metastatic 15Ovarian Neoplasms 14Breast Neoplasms, Male 14

Interventions

Gemcitabine 6Fluorouracil 5Leucovorin 4Irinotecan 3Albumin-Bound Paclitaxel 3pembrolizumab 2irinotecan sucrosofate 2Oxaliplatin 24-fluorobenzoyl-TN-14003 2zolbetuximab 1regorafenib 1olaparib 1ibrutinib 1beta-D-glucosylisophosphoramide mustard 1adavosertib 1Tetrahydrouridine 1Telemedicine 1Taxes 1Practice Guidelines as Topic 1Paclitaxel 1PEGPH20 1Erlotinib Hydrochloride 1Drug Therapy 1Docetaxel 1Decitabine 1Counseling 1Cisplatin 1Capecitabine 1BKT140 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Pancreatic Adenocarcinoma × Capecitabine × Clear all
NCT02324543 2023-07-21

Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
47 enrolled 22 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡